Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Kyle A. Beckwith · SciRah

Researcher profile · Semantic Scholar

Kyle A. Beckwith

Share profile

Kyle A. Beckwith — researcher profile on SciRah

h-index: 13
Works: 26
Citations: 2,116

Most-cited papers

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.
J. Dubovsky, Kyle A. Beckwith, G. Natarajan, J. Woyach +25 more
2013Blood762 citations Open access
Semantic Scholar
Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia.
J. Fraietta, Kyle A. Beckwith, Prachi R. Patel, M. Ruella +23 more
2016Blood460 citations Open access
Semantic Scholar
Ibrutinib treatment improves T cell number and function in CLL patients
Meixiao Long, Kyle A. Beckwith, Priscilla Do, B. Mundy +16 more
2017Journal of Clinical Investigation359 citations Open access
Semantic Scholar
Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.
Zachary A. Hing, Rose Mantel, Kyle A. Beckwith, Daphne Guinn +8 more
2015Blood89 citations Open access
Semantic Scholar
Toll-Like Receptors and Dectin-1, a C-Type Lectin Receptor, Trigger Divergent Functions in CNS Macrophages
J. Gensel, Yan Wang, Z. Guan, Kyle A. Beckwith +4 more
2015Journal of Neuroscience75 citations Open access
Semantic Scholar
Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease
E. Hertlein, Kyle A. Beckwith, G. Lozanski, Timothy L Chen +16 more
2013PLoS ONE63 citations Open access
Semantic Scholar
Tetraspanins as therapeutic targets in hematological malignancy: a concise review
Kyle A. Beckwith, J. Byrd, N. Muthusamy
2015Frontiers in Physiology58 citations Open access
Semantic Scholar
Selinexor suppresses Downstream Effectors of B-cell activation, proliferation and migration in chronic lymphocytic leukemia cells
Yiming Zhong, Dalia El-Gamal, J. Dubovsky, Kyle A. Beckwith +14 more
2014Leukemia57 citations Open access
Semantic Scholar
The impact of increasing karyotypic complexity and evolution on survival in CLL patients treated with ibrutinib.
A. Kittai, Cecelia R. Miller, D. Goldstein, Ying Huang +10 more
2021Blood50 citations Open access
Semantic Scholar
The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model
Kyle A. Beckwith, Frank W. Frissora, Matthew R. Stefanovski, William H. Towns +11 more
2014Leukemia40 citations Open access
Semantic Scholar
Leukemic B Cell CTLA-4 Suppresses Co-stimulation of T cells
Priscilla Do, Kyle A. Beckwith, C. Cheney, Minh H Tran +8 more
2019Journal of Immunology31 citations Open access
Semantic Scholar
OSU-T315: a novel targeted therapeutic that antagonizes AKT membrane localization and activation of chronic lymphocytic leukemia cells.
Ta-Ming Liu, Yong-Hua Ling, J. Woyach, Kyle A. Beckwith +14 more
2015Blood26 citations Open access
Semantic Scholar
Patient characteristics that predict Richter's transformation in patients with chronic lymphocytic leukemia treated with ibrutinib
A. Kittai, Ying Huang, Kyle A. Beckwith, S. Bhat +8 more
2022American journal of hematology/oncology22 citations
Semantic Scholar
Ibrutinib Represents a Novel Class of Immune Modulating Therapeutics That Enhances the Survival of Activated T Cells in Vitro and In Vivo through a Non-BTK Mediated Mechanism
Meixiao Long, Kyle A. Beckwith, Priscilla Do, Mundy L Bethany +15 more
20166 citations
Semantic Scholar
Ibrutinib Treatment Reduces Both T-Regulatory Cells and B-Regulatory Cell Phenotype in Malignant B Cells in Chronic Lymphocytic Leukemia Patients
Meixiao Long, Kyle A. Beckwith, K. Maddocks, C. Cheney +4 more
20155 citations
Semantic Scholar
BI 836826, a Novel Fc-Engineered Antibody in Combination with Phosphoinositide-3-Kinase Inhibitor for Treatment of High Risk Chronic Lymphocytic Leukemia
D. Stephens, Kyle A. Beckwith, C. Cheney, X. Mo +6 more
20144 citations
Semantic Scholar
Utilizing Clinical Features of Progression to Predict Richter's Syndrome in Patients with CLL Progressing after Ibrutinib
A. Kittai, Ying Huang, Ashleigh Keiter, Kyle A. Beckwith +7 more
2021Blood3 citations Open access
Semantic Scholar
Leukemic cell expressed CTLA-4 suppresses T cells via down-modulation of CD80 by trans-endocytosis
Priscilla Do, Kyle A. Beckwith, Larry P. Beaver, Brittany G. Griffin +6 more
2016Journal of Immunology3 citations
Semantic Scholar
Ibrutinib Is an Irreversible Molecular Inhibitor of Interleukin-2 Inducible Kinase: Expanding Therapeutic Potential and Modulating a Th1 Selective Pressure in CD4 T-Cells
J. Dubovsky, Kyle A. Beckwith, J. Woyach, S. Jaglowski +20 more
20123 citations
Semantic Scholar
Increasing Karyotypic Complexity Predicts Outcomes in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib
D. Goldstein, Kyle A. Beckwith, Cecelia R. Miller, Ying Huang +10 more
20202 citations Open access
Semantic Scholar
The Role of Tetraspanin CD37 in B-Cell Malignancy
Kyle A. Beckwith, E. Williams, M. Wright, A. V. van Spriel +2 more
20152 citations
Semantic Scholar
Novel Immunotherapeutic Strategies for Chronic Lymphocytic Leukemia
Kyle A. Beckwith
2016OhioLink ETD Center (Ohio Library and Information Network)0 citations Open access
Semantic Scholar
Title: Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1 selective pressure in T-lymphocytes Short Title: Ibrutinib is an immunomodulatory ITK inhibitor
J. Dubovsky, Kyle A. Beckwith, G. Natarajan, S. Jaglowski +22 more
20160 citations
Semantic Scholar
Abstract B041: Ibrutinib treatment counteracts the immunosuppressive activity of malignant B cells
Meixiao Long, Kyle A. Beckwith, Priscilla Do, Amber L. Gordon +10 more
20160 citations
Semantic Scholar
Abstract 492: Ibrutinib inhibits Interleukin-2 inducible kinase, driving a Th1 selective pressure in human leukemia patients that serves to alleviate tumor-induced immunosupression.
J. Dubovsky, Kyle A. Beckwith, G. Natarajan, J. Woyach +23 more
20130 citations
Semantic Scholar
A Transgenic Mouse Model of Aggressive B-Cell Malignancy for Evaluating Anti-Human CD37 Therapeutics
Kyle A. Beckwith, Frank W. Frissora, Matthew R. Stefanovski, J. Deckert +5 more
20120 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

J. Byrd×21
Invite
J. Byrd — researcher profile on SciRah
N. Muthusamy×16
Invite
N. Muthusamy — researcher profile on SciRah
J. Woyach×14
Invite
J. Woyach — researcher profile on SciRah
K. Maddocks×13
Invite
K. Maddocks — researcher profile on SciRah

Jeffrey A. Jones

×11

Invite

Jeffrey A. Jones — researcher profile on SciRah

Invite

A. Johnson — researcher profile on SciRah

L. Andritsos×10

Invite

L. Andritsos — researcher profile on SciRah

Invite

A. Lehman — researcher profile on SciRah

Invite

J. Flynn — researcher profile on SciRah

Invite

C. Cheney — researcher profile on SciRah

Matthew R. Stefanovski×6

Invite

Matthew R. Stefanovski — researcher profile on SciRah

Frank W. Frissora×6

Invite

Frank W. Frissora — researcher profile on SciRah